1
|
Pešić A, Vuković V, Kozarac S, Otašević V, Bibić T, Mihaljević B, Antić D. Unique presentation of T-cell/histiocyte-rich large B cell lymphoma complicated with hemophagocytic lymphohistiocytosis: Case report and review of the literature. J Med Biochem 2024; 43:631-637. [PMID: 39139166 PMCID: PMC11318850 DOI: 10.5937/jomb0-48290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 12/23/2023] [Indexed: 08/15/2024] Open
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare, lifethreatening hyperinflammatory disorder characterized by dysfunction of NK cells and cytotoxic lymphocytes. We present a rare case of a patient diagnosed with HLH who presented with persistent fever during treatment for refractory T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL), highlighting the challenges of managing HLH in the context of refractory lymphoma. According to our review of the literature, this is the first case of HLH that developed several months into treatment for refractory TCHRLBCL and not in close temporal relation to lymphoma diagnosis.
Collapse
Affiliation(s)
- Andrej Pešić
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| | - Vojin Vuković
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| | - Sofija Kozarac
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| | - Vladimir Otašević
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| | - Tamara Bibić
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| | | | - Darko Antić
- University Clinical Center of Serbia, Clinic for Hematology, Belgrade
| |
Collapse
|
2
|
Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, Lazareth A, Bouafia F, Pica GM, Orsini-Piocelle F, Rocher C, Gros FX, Parrens M, Dony A, Rossi C, Ghesquières H, Bachy E, Traverse-Glehen A, Sarkozy C. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv 2021; 5:3227-3239. [PMID: 34427583 PMCID: PMC8405194 DOI: 10.1182/bloodadvances.2021004515] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 04/21/2021] [Indexed: 12/16/2022] Open
Abstract
In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV- DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients.
Collapse
Affiliation(s)
- Estelle Bourbon
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
| | - Delphine Maucort-Boulch
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
- Service de Biostatistique et Bioinformatique, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France
- Centre national de la recherche scientifique (CNRS), Unité Mixte de Recherche (UMR) 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France
| | - Juliette Fontaine
- Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Claire Mauduit
- Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Pierre Sesques
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Violaine Safar
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Emmanuelle Ferrant
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Camille Golfier
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Dana Ghergus
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Lionel Karlin
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Anne Lazareth
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Fadhela Bouafia
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
| | - Gian Matteo Pica
- Service d'Hématologie, Centre hospitalier Métropole Savoie, Chambéry, France
| | | | - Clément Rocher
- Service d'Hématologie, Groupement Hospitalier Nord Dauphiné, Bourgoin Jallieu, France
| | | | - Marie Parrens
- Service d'Anatomie et de Pathologie, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France
- INSERM U1053, BaRITOn, Université de Bordeaux, Bordeaux, France
| | - Arthur Dony
- Service d'Hématologie, Hôpital Nord-Ouest, Villefranche-sur-Saône, France
| | - Cédric Rossi
- Service d'Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France
- INSERM UMR 1231, Dijon, France
| | - Hervé Ghesquières
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
- EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and
| | - Emmanuel Bachy
- Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
- EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and
| | - Alexandra Traverse-Glehen
- Université de Lyon, Université Claude Bernard Lyon 1, Villeurbanne, France
- Service d'Anatomie Pathologique, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Bénite Cedex, France
- EA LIB (Lymphoma ImmunoBiology), Université Claude Bernard Lyon 1, Lyon, France; and
| | - Clémentine Sarkozy
- Département d'Innovation thérapeutique, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|